Amgen touts its latest cut of longterm Repatha data, still hunting elusive billions for PCSK9 franchise

It took 5 years for Amgen to move its PCSK9 cholesterol drug Repatha into the blockbuster column, all while waging an unending legal war over the patents related to Sanofi and Regeneron’s rival. But the Big Pharma player is still actively promoting every new cut of the data in its...

Click to view original post